Histone methyltransferase

Histone Lysine N Methyltransferase EZH2, Pipeline Review, H2 2019 - Domainex Ltd, Kainos Medicine Inc, Epizyme Inc & Pfizer Inc - ResearchAndMarkets.com

Retrieved on: 
Thursday, January 16, 2020
Biotechnology, Pharmaceutical, Genetics, Health, Branches of biology, Epigenetics, EZH2, Ezh2 gene, Proteins, Protein families, N-methyltransferase, Histone methyltransferase, Histone, EZH1, Polycomb Group Proteins and Cancer

The "Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019'; Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) pipeline Target constitutes close to 19 molecules.
  • Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) - Enhancer of zeste homolog 2 (EZH2) is a histone-lysine N-methyltransferase enzyme encoded by EZH2 gene.
  • The report 'Histone Lysine N Methyltransferase EZH2 - Pipeline Review, H2 2019' outlays comprehensive information on the Histone Lysine N Methyltransferase EZH2 (ENX 1 or Enhancer Of Zeste Homolog 2 or Lysine N Methyltransferase 6 or EZH2 or EC 2.1.1.43) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.